Owing to its mechanism of selectively inducing apoptosis via DR4/DR5 on the surface of target cells, rhTRAIL and DR4/DR5 agonistic antibodies have been developed, demonstrating their safety and tolerability in various clinical trials for cancer treatment (Table S1). Here, TNFRSF10B is linked to cancer.